International Journal of Endocrinology and Metabolism

Published by: Kowsar

Depicting Medullary Thyroid Cancer Recurrence: The Past and the Future of Nuclear Medicine Imaging

Evangelia Skoura 1 , *
Author Information
1 Nuclear Medicine Department, Evangelismos Hospital, Athens, Greece
Article information
  • International Journal of Endocrinology and Metabolism: October 01, 2013, 11 (4); e8156
  • Published Online: October 1, 2013
  • Article Type: Review Article
  • Received: September 13, 2012
  • Revised: January 25, 2013
  • Accepted: February 1, 2013
  • DOI: 10.5812/ijem.8156

To Cite: Skoura E. Depicting Medullary Thyroid Cancer Recurrence: The Past and the Future of Nuclear Medicine Imaging, Int J Endocrinol Metab. 2013 ; 11(4):e8156. doi: 10.5812/ijem.8156.

Copyright © 2013, Research Institute For Endocrine Sciences and Iran Endocrine Society. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Radiopharmaceuticals
3. <sup>18</sup>F-DOPA
4. <sup>68</sup> Ga-labelled Somatostatin Analogues
5. Conclusions
  • 1. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009; 19(6): 565-612[DOI][PubMed]
  • 2. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004; 61(3): 299-310[DOI][PubMed]
  • 3. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008; 4(1): 22-32[DOI][PubMed]
  • 4. Franc S, Niccoli-Sire P, Cohen R, Bardet S, Maes B, Murat A, et al. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2001; 55(3): 403-409[DOI]
  • 5. Modigliani Elisabeth, Cohen Regis, Campos Jose-Marie, Conte-Devolx Bernard, Maes Beatrice, Boneu Andree, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf). 1998; 48(3): 265-273[DOI]
  • 6. Rufini Vittoria, Castaldi Paola, Treglia Giorgio, Perotti Germano, Gross Milton D, Al-Nahhas Adil, et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomedicine &amp; Pharmacotherapy. 2008; 62(3): 139-146[DOI]
  • 7. Szakall S, Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med. 2002; 43(1): 66-71[PubMed]
  • 8. Skoura Evangelia, Papachristou Maria, Datseris Ioannis E. The Role of Nuclear Medicine in Imaging and Therapy of Neuroendocrine Tumors. Hospital Chronicles. 2012; 7(2): 81-90
  • 9. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging. 2004; 48(2): 150-63[PubMed]
  • 10. Clarke S, Εll PJ, Gambhir SS. Medullary thyroid cancer. 2004; : 165-174
  • 11. Verga U, Muratori F, Di Sacco G, Banfi F, Libroia A. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma. Henry Ford Hosp Med J. 1989; 37(3-4): 175-7[PubMed]
  • 12. Clarke S, Lazarus C, Maisey M. Experience in imaging medullary thyroid carcinoma using 99mTc (V) dimercaptosuccinic acid (DMSA). Henry Ford Hosp Med J. 1989; 37(3-4): 167-8[PubMed]
  • 13. Bombardieri E, Coliva A, Maccauro M, Seregni E, Orunesu E, Chiti A, et al. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2010; 54(1): 3-15[PubMed]
  • 14. Sandrock D, Blossey HC, Steinroeder M, Munz DL. Contribution of different scintigraphic techniques to the management of medullary thyroid carcinoma. Henry Ford Hosp Med J. 1989; 37(3-4): 173-4[PubMed]
  • 15. Baulieu Jean-Louis, Guilloteau Denis, Delisle Marie-Joelle, Perdrisot Remy, Gardet Paule, Delépine Nicole, et al. Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer: A French cooperative study. Cancer. 1987; 60(9): 2189-2194[DOI]
  • 16. Kwekkeboom DJ, Reubi J, Krenning EP, Ell PJ, Gambhir SS. Peptide receptor scintigraphy in oncology. 2004; : 97-106
  • 17. Hicks RJ. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging. 2010; 10 Spec no A-91[DOI][PubMed]
  • 18. Arslan N, Ilgan S, Yuksel D, Serdengecti M, Bulakbasi N, Ugur O, et al. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med. 2001; 26(8): 683-8[PubMed]
  • 19. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab. 1996; 81(7): 2541-4[PubMed]
  • 20. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001; 86(2): 895-902[PubMed]
  • 21. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 1991; 64(4): 567-73[PubMed]
  • 22. Behr TM, Becker W. Metabolic and receptor imaging of metastatic medullary thyroid cancer: does anti-CEA and somatostatin-receptor scintigraphy allow for prognostic predictions? Eur J Nucl Med. 1999; 26(1): 70-1[PubMed]
  • 23. Plachcinska A, Mikolajczak R, Maecke H, Mlodkowska E, Kunert-Radek J, Michalski A, et al. Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a pilot study. Cancer Biother Radiopharm. 2004; 19(2): 261-70[DOI][PubMed]
  • 24. Czepczynski R, Parisella MG, Kosowicz J, Mikolajczak R, Ziemnicka K, Gryczynska M, et al. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007; 34(10): 1635-45[DOI][PubMed]
  • 25. Arnstein NB, Juni JE, Sisson JC, Lloyd RV, Thompson NW. Recurrent medullary carcinoma of the thyroid demonstrated by thallium-201 scintigraphy. J Nucl Med. 1986; 27(10): 1564-8[PubMed]
  • 26. Hoefnagel CA, Delprat CC, Marcuse HR, de Vijlder JJ. Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med. 1986; 27(12): 1854-7[PubMed]
  • 27. Learoyd DL, Roach PJ, Briggs GM, Delbridge LW, Wilmshurst EG, Robinson BG. Technetium-99m-sestamibi scanning in recurrent medullary thyroid carcinoma. J Nucl Med. 1997; 38(2): 227-30[PubMed]
  • 28. Ugur Omer, Kostakoglu Lale, Hui Edmond T, Fisher Darrell R, Garmestani Kayhan, Gansow Otto A, et al. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: Dosimetry calculations incorporating cross-organ beta doses. Nucl Med Biol. 1996; 23(1): 1-8[DOI]
  • 29. Behr Thomas M, Gratz Stefan, Markus Peter M, Dunn Robert M, Hüfner Michael, Schauer Alfred, et al. Anti‐carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma. Cancer. 1997; 80: 2436-2457
  • 30. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984; 53(2): 278-85[PubMed]
  • 31. Laverman P, Sosabowski JK, Boerman OC, Oyen WJ. Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging. 2012; 39 Suppl 1-92[DOI][PubMed]
  • 32. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996; 67(5): 644-7[DOI][PubMed]
  • 33. Behr TM, Jenner N, Behe M, Angerstein C, Gratz S, Raue F, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med. 1999; 40(6): 1029-44[PubMed]
  • 34. Froberg AC, de Jong M, Nock BA, Breeman WA, Erion JL, Maina T, et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009; 36(8): 1265-72[DOI][PubMed]
  • 35. Gotthardt M, Behe MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2006; 33(11): 1273-9[DOI][PubMed]
  • 36. Ambrosini V, Tomassetti P, Franchi R, Fanti S. Imaging of NETs with PET radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2010; 54(1): 16-23[PubMed]
  • 37. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol. 2004; 11(8): 786-94[DOI][PubMed]
  • 38. Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control. 2005; 12(4): 254-60[PubMed]
  • 39. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med. 2000; 27(5): 490-6[PubMed]
  • 40. Iagaru A, Masamed R, Singer PA, Conti PS. Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. Mol Imaging Biol. 2007; 9(2): 72-7[DOI][PubMed]
  • 41. Skoura E, Datseris IE, Rondogianni P, Tsagarakis S, Tzanela M, Skilakaki M, et al. Correlation between Calcitonin Levels and [(18)F]FDG-PET/CT in the Detection of Recurrence in Patients with Sporadic and Hereditary Medullary Thyroid Cancer. ISRN Endocrinol. 2012; 2012: 375231[DOI][PubMed]
  • 42. Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, et al. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun. 2010; 31(6): 567-75[DOI][PubMed]
  • 43. Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, et al. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol. 2008; 34(5): 581-6[DOI][PubMed]
  • 44. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, et al. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol. 2010; 12(5): 547-53[DOI][PubMed]
  • 45. Ong SC, Schoder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gonen M, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007; 48(4): 501-7[PubMed]
  • 46. Pestourie C, Theze B, Kuhnast B, Le Helleix S, Gombert K, Dolle F, et al. PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[(18)F]F-L-DOPA. Eur J Nucl Med Mol Imaging. 2010; 37(1): 58-66[DOI][PubMed]
  • 47. Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007; 34(10): 1604-9[DOI][PubMed]
  • 48. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001; 28(1): 64-71[PubMed]
  • 49. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008; 49(4): 524-31[DOI][PubMed]
  • 50. Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. Eur J Surg Oncol. 2010; 36(4): 414-21[DOI][PubMed]
  • 51. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010; 20(5): 527-33[DOI][PubMed]
  • 52. Wong KK, Laird AM, Moubayed A, Chondrogiannis S, Marzola MC, Evangelista L, et al. How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals. Nucl Med Commun. 2012; 33(7): 679-88[DOI][PubMed]
  • 53. Gourgiotis L, Sarlis NJ, Reynolds JC, VanWaes C, Merino MJ, Pacak K. Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab. 2003; 88(2): 637-41[PubMed]
  • 54. Ilias I, Pacak K. A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol. 2008; 35 Suppl 1-34[DOI][PubMed]
  • 55. Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EG, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol. 2009; 71(3): 199-213[DOI][PubMed]
  • 56. Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009; 30(4): 281-6[DOI][PubMed]
  • 57. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007; 34(7): 982-93[DOI][PubMed]
  • 58. Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010; 37(1): 49-57[DOI][PubMed]
  • 59. Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012; 39(4): 569-80[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments